🌍 Un estudi pioner de l'#hbellvitge, IDIBELL i CIBERINFEC, publicat a JAMA Network Open, revela que els dies que augmenta la contaminació de l’aire, també ho fa el consum d’antibiòtics💊. S'han recopilat dades diàries de PM10, PM2.5, NO2 i prescripcions d’antibiòtics a les

Make sure you cast your vote in the Amazing case race!! IASLC #WCLC24 #iaslcacademy form.jotform.com/242185215392152

Presented at #ESMO24: Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy. Full ADRIATIC trial results: nej.md/4d0eZ5m

Dr. Suresh Senan presents key subgroups from practice-changing ph3 ADRIATIC Trial -- PCI, platinum choice (carbo/cis), RT schedule (BID/QD). Benefit most pronounced w/ carbo > cis. Comparable between PCI (Y/N) & RT schedule. #ESMO24.

🔥🚨OncoAlert Hot off the press. Just published NEJM in conjunction with presentation ESMO - Eur. Oncology #ESMO24 Results of #Positive Phase 2 trial of #Ponsegromab (#GDF15 inhibitor) vs #Placebo for treatment of #Cachexia in patients with #Cancer. 👇🏼 nejm.org/doi/full/10.10…

A salutary tale about the state of cancer services in England. Saddened to see lung doing so badly despite huge efforts by staff. Suggests structural issues. Important to remember the velocity of this disease causes performance status decline and stage up shifting within weeks.

Accèssit del Premi Dr. Carles Vallbona i Calbó per al Dr. Bernat Bertran El metge adjunt del Servei de #Neurologia i investigador de l’HMar Research Institute, ha rebut el guardó a l’#ActeProfessioCoMB organitzat pel Col·legi Metges BCN hospitaldelmar.cat/ca/noticies/vi…

Sanidad ultima los siguientes pasos de su plan antitabaco: – Prohibir la venta cigarrillos electrónicos desechables – El fin de los saborizantes – Establecer un empaquetado genérico o neutro para el tabaco Aquí tienes más detalles eldiario.es/sociedad/sigui…

Real world study of chemo-immunotherapy in #SCLC JTO & JTO CRR. 436 pts from 10 British & 10 Swiss institutions, 33% would not have been eligible for IMpower 133 / CASPIAN trials. PFS 5.5m, OS 9.3m. Similar to other real world studies: MAURIS & IMfirst. jtocrr.org/article/S2666-…

Excited to share our work on RWE in ES-SCLC: 🎉 First-line chemo-immunotherapy in SCLC: outcomes of a binational real-world study - JTO Clinical and Research Reports jtocrr.org/article/S2666-… Núria Zellweger Raffaele Califano Sacha Rothschild

Great opportunity to join an amazing team!! 🙌🙌

🆕 opportunity! 🧑‍⚕️Interested in novel IO & cell therapy in solid cancer? Keen to gain experience in early phase trials? Come join Fiona, me & our amazing team as a ‘Clinical Fellow in Advanced Immunotherapy & Cell Therapy Team’. Deadline 27 Nov 2024 👇 healthjobsuk.com/job/v6778827

Fundació Horta Sud. Fiable 100% y del lugar en el que están casi todos los pueblos y ciudades más afectadas. Puedes donar directamente aquí. fundaciohortasud.helpbysc.com/afectados-dana

Federació d’Associacions Veïnals de València (FAAVV) 100% fiable, para enviar material. faavv.es/dana/

Super session at #VIIISimposioICAPEM on lung cancer clinical trials, fascinating that: - more 🚺 take part to trials when lead authors are 🚺! - 🚺 take part in less lung cancer clinical trials v 🚹 - ENGAGE study will aim to understand why ESMO - Eur. Oncology Women4Oncology #LCSM

A wonderful and important training, for which I'm very grateful to IASLC ! I highly recommend it 😁💪 Francesco Cortiula Laura Moliner Pedro Rocha Alessandro Di Federico

Excellent paper! Includes England lung cancer never smoking freq by ethnicity. 6.7% of lung cancer are never smokers in White, 38.3% in Indian, 31.6% in Pakistani, 11.3% in Bangladeshi, 14.9% in Caribbean, 39.2% in Black African, & 44.5% in Chinese ethnicities Ruth Strauss Foundation

Nicolas Girard et al report on the named patient use of #lurbinectedin in France 🇫🇷 for pts with relapsed SCLC. IFCT-2105 LURBICLIN study (n=312) #LCSM 🟦 Efficacy: ORR 22%, DCR38%, PFS 1.9 months, OS 4.7 months 🟩 Safety: 14% Grade 3-4 TRAEs sciencedirect.com/science/articl…

One of the forgotten costs of cancer therapy is time spent in the clinic. Report on time toxicity JCO Oncology Practice on pts with lung cancer showed 22% of days alive had in person visits: 24% with chemotherapy, 21% for immunotherapy, 16% for targeted therapy. ascopubs.org/doi/10.1200/OP…

Presented at #ASCO25 and published in NEJM: Tarlatamab, a DLL3-targeting bispecific T-cell engager, significantly improves overall survival vs chemo in 2L #SCLC (13.6 vs 8.3 mo). 👏 Congrats to VHIO's researcher Pedro Rocha for contributing to this pivotal trial ‼️ ➡️